Sermonix Pharmaceuticals, founded by David Portman, MD—a leading clinical researcher and expert in women’s health—focuses on developing targeted therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers.
Our ELAINE Studies are evaluating an investigational oral drug, lasofoxifene, a novel targeted endocrine agent, in women and men with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2-) breast cancer harboring an ESR1 mutation(s).
Company Details
- Employees
- 14
- Founded
- 2014
- Address
- 250 E Broad St,
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://sermonixpharma.com/
- HQ
- Columbus, Ohio
Sermonix Pharmaceuticals Questions
Sermonix Pharmaceuticals's website is https://sermonixpharma.com/
Sermonix Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/sermonix-pharmaceuticals
Sermonix Pharmaceuticals has
14 employees.
View email and phone details for 14
employees at Sermonix Pharmaceuticals.
Sermonix Pharmaceuticals's industry is
Pharmaceutical Manufacturing
Sermonix Pharmaceuticals's top competitors are
Slate Run Pharmaceuticals,
Kurome Therapeutics, Inc.,
Luca Biologics,
Convelo Therapeutics, Inc,
Sollis,
Clarametyx Biosciences,
Diasome Pharmaceuticals, Inc.,
Basking Biosciences Inc,
Regor Therapeutics Group,
Henlius.
Sermonix Pharmaceuticals's categories are Pharmaceutical Manufacturing
Sermonix Pharmaceuticals's founding year is 2014
